Section Arrow
NTLA.NASDAQ
- Intellia Therapeutics
Quotes are at least 15-min delayed:2026/06/25 17:42 EDT
After Hours
Last
 15.818
-0.212 (-1.32%)
Bid
15.8
Ask
16.01
High 16.09 
Low 15.7041 
Volume 93.93K 
Regular Hours (Closed)
Last
 16.03
+0.53 (+3.42%)
Day High 
16.26 
Prev. Close
15.5 
1-M High
16.73 
Volume 
3.47M 
Bid
15.8
Ask
16.01
Day Low
15.575 
Open
15.62 
1-M Low
11.81 
Market Cap 
2.17B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.35 
20-SMA 13.96 
50-SMA 13.86 
52-W High 28.25 
52-W Low 7.95 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.52/0.20
Enterprise Value
2.23B
Balance Sheet
Book Value Per Share
4.44
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
0.38
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TECHBio-Techne Corp70.7+11.825+20.08%84.11PE
After Hours 70.55 -0.15 -0.21%
HUMAHumacyte0.62-0.0777-11.14%-- 
After Hours 0.6514 +0.0314 +5.06%
NUVBNuvation Bio5.81-0.65-10.06%-- 
After Hours 5.81 0 0.00%
RXRXRecursion Pharmaceuticals3.34+0.11+3.41%-- 
After Hours 3.35 +0.01 +0.30%
SLSSELLAS Life Sciences Group10.53+1.36+14.83%-- 
After Hours 10.56 +0.03 +0.28%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.